ArticleLiver cancer2024

PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma.

Ghassan K Abou-Alfa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.